肺癌中循环血管内皮生长因子的检测方法及价值评估
Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.
作者信息
Guo Sumin, Martin Michael G, Tian Cheng, Cui Jinglin, Wang Lishi, Wu Shucai, Gu Weikuan
机构信息
Department of Oncology, Hebei Chest Hospital, Lung Cancer Control and Prevention Center of Hebei Province, Shijiazhuang, Hebei, 050041, China.
Department of Orthopaedic Surgery- Campbell Clinic and Pathology, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
出版信息
J Cancer. 2018 Mar 22;9(7):1287-1300. doi: 10.7150/jca.22020. eCollection 2018.
Abstract
Lung cancer is the deadliest cancer in the world. Angiogenesis plays a crucial role of the incidence, progression, and metastasis in lung cancer. Angiogenesis inhibitors are used to treat non-small cell lung cancer (NSCLC) patients, and the molecular biomarkers are also being assessed to predict treatment response/therapeutic response and patients' prognosis. Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates angiogenesis. Due to its predictive values of prognosis on NSCLC, a large number of methods have been developed and evaluated to detect VEGF levels in a variety of studies. In this article, we review the detection methods designed to measure the VEGF levels in different body fluids and prognosticate the value of VEGF in treatment, diagnosis and survival in lung cancer.
摘要
肺癌是全球最致命的癌症。血管生成在肺癌的发生、发展和转移过程中起着关键作用。血管生成抑制剂被用于治疗非小细胞肺癌（NSCLC）患者，同时也在评估分子生物标志物以预测治疗反应/疗效及患者的预后。血管内皮生长因子（VEGF）是一种由细胞产生的信号蛋白，可刺激血管生成。由于其对NSCLC预后具有预测价值，在众多研究中已开发并评估了大量检测VEGF水平的方法。在本文中，我们综述了旨在测量不同体液中VEGF水平并预测VEGF在肺癌治疗、诊断和生存方面价值的检测方法。
相似文献
1
Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.肺癌中循环血管内皮生长因子的检测方法及价值评估
J Cancer. 2018 Mar 22;9(7):1287-1300. doi: 10.7150/jca.22020. eCollection 2018.
2
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.血管内皮生长因子表达在肺癌患者中的预后价值：一项荟萃分析的系统评价
J Thorac Oncol. 2009 Sep;4(9):1094-103. doi: 10.1097/JTO.0b013e3181a97e31.
3
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.血管内皮生长因子 A 和血管内皮生长因子受体 2 在非小细胞肺癌患者中的表达：与预后的关系。
Lung Cancer. 2009 Dec;66(3):314-8. doi: 10.1016/j.lungcan.2009.02.013. Epub 2009 Mar 25.
4
microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.微小RNA-128通过直接靶向血管内皮生长因子-C，在人类非小细胞肺癌的肿瘤发生、血管生成和淋巴管生成中发挥关键作用。
Eur J Cancer. 2014 Sep;50(13):2336-50. doi: 10.1016/j.ejca.2014.06.005. Epub 2014 Jul 4.
5
Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.血清血管内皮生长因子和血管生成素-2在肺癌患者中的预后意义。
Tuberk Toraks. 2015 Jun;63(2):71-7. doi: 10.5578/tt.9015.
6
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.血管内皮生长因子在Ⅰ期非小细胞肺癌中的表达与新生血管形成及预后不良相关。
Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9. doi: 10.1007/s10434-001-0072-y.
7
Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.循环血清血管内皮生长因子不是非小细胞肺癌的预后因素。
J Thorac Oncol. 2008 Oct;3(10):1119-26. doi: 10.1097/JTO.0b013e318187464e.
8
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.非小细胞肺癌中的血管生成：肿瘤及血液中新生血管生成以及细胞因子血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）的预后影响
Lung Cancer. 2006 Feb;51(2):143-58. doi: 10.1016/j.lungcan.2005.09.005. Epub 2005 Dec 19.
9
10
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis].[血管内皮生长因子与肺癌患者的生存率：一项系统文献综述和荟萃分析]
Rev Mal Respir. 2002 Oct;19(5 Pt 1):577-84.
引用本文的文献
1
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.阿法替尼或贝伐珠单抗联合奥希替尼可有效控制非小细胞肺癌原位动物模型中的肿瘤发展。
PLoS One. 2024 Jun 27;19(6):e0304914. doi: 10.1371/journal.pone.0304914. eCollection 2024.
2
Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.2000年至2022年肿瘤标志物在肺癌诊断中应用的文献计量学与可视化分析
Cancer Innov. 2023 May 19;2(4):265-282. doi: 10.1002/cai2.74. eCollection 2023 Aug.
3
Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis.评估肺癌诊断前的血液蛋白测量值以预测生存。
EBioMedicine. 2023 Jun;92:104623. doi: 10.1016/j.ebiom.2023.104623. Epub 2023 May 24.
4
The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinum-based chemoradiation.血管内皮生长因子和骨桥蛋白表达与接受铂类同步放化疗的局部晚期鼻咽癌患者3年无进展生存期的关系
Contemp Oncol (Pozn). 2022;26(3):220-228. doi: 10.5114/wo.2022.120698. Epub 2022 Oct 24.
5
Elevated serum Cripto-1 and VEGF levels in patients with non-small cell lung cancer.非小细胞肺癌患者血清Cripto-1和血管内皮生长因子水平升高。
FASEB Bioadv. 2022 May 3;4(8):539-546. doi: 10.1096/fba.2022-00002. eCollection 2022 Aug.
6
Differentiation of brain metastases from small and non-small lung cancers using apparent diffusion coefficient (ADC) maps.利用表观扩散系数（ADC）图区分小细胞肺癌和非小细胞肺癌脑转移瘤。
BMC Med Imaging. 2021 Apr 15;21(1):70. doi: 10.1186/s12880-021-00602-7.
7
Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy.细胞外囊泡相关的微小RNA作为液体活检中肺癌的生物标志物
Front Mol Biosci. 2021 Feb 24;8:630718. doi: 10.3389/fmolb.2021.630718. eCollection 2021.
8
Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer.血清VEGF-A水平和全身免疫炎症指数在小细胞肺癌中的诊断及预测价值评估
J Cancer. 2021 Jan 1;12(5):1356-1364. doi: 10.7150/jca.51972. eCollection 2021.
9
Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies.肾素-血管紧张素系统的种系基因变异、缺氧与非小细胞肺癌进展中的血管生成：发现与验证研究
Cancers (Basel). 2020 Dec 18;12(12):3834. doi: 10.3390/cancers12123834.
10
Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.贝伐单抗联合化疗治疗肺腺癌有症状脑转移瘤的疗效和安全性：一项回顾性分析
J Thorac Dis. 2019 Nov;11(11):4725-4734. doi: 10.21037/jtd.2019.10.49.
本文引用的文献
1
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
2
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.一项比较紫杉醇-卡铂-贝伐珠单抗联合或不联合硝酸甘油贴剂治疗 IV 期非鳞状非小细胞肺癌患者的随机 II 期研究：NVALT12（NCT01171170）†。
Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.
3
Influence of video-assisted thoracoscopic lobectomy on immunological functions in non-small cell lung cancer patients.电视辅助胸腔镜肺叶切除术对非小细胞肺癌患者免疫功能的影响。
Med Oncol. 2015 Jul;32(7):201. doi: 10.1007/s12032-015-0639-2. Epub 2015 Jun 17.
4
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).口服节拍性长春瑞滨作为老年晚期非小细胞肺癌患者的一线治疗：一项II期试验（MOVE试验）的结果
BMC Cancer. 2015 May 6;15:359. doi: 10.1186/s12885-015-1354-2.
5
Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.树突状细胞免疫疗法联合细胞因子诱导的杀伤细胞可促进转移性非小细胞肺癌患者向Th2细胞因子谱偏移。
Int Immunopharmacol. 2015 Apr;25(2):450-6. doi: 10.1016/j.intimp.2015.02.010. Epub 2015 Feb 16.
6
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
7
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.临床基因分型与疗效结果：非鳞状非小细胞肺癌一线贝伐单抗联合化疗的II期ABIGAIL研究中的探索性生物标志物数据。
Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2.
8
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).贝伐珠单抗联合卡铂为基础的化疗治疗晚期非鳞状非小细胞肺癌的相关性生物标志物分析：Ⅱ期随机 ABIGAIL 研究（BO21015）的结果。
J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.
9
Influence of erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer.莪术消癥汤对非小细胞肺癌血瘀毒结证血管生成的影响。
J Tradit Chin Med. 2013 Jun;33(3):303-6. doi: 10.1016/s0254-6272(13)60169-7.
10
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.贝伐珠单抗联合卡铂紫杉醇治疗伴有恶性胸腔积液的非小细胞肺癌的 II 期研究。
Med Oncol. 2013;30(3):676. doi: 10.1007/s12032-013-0676-7. Epub 2013 Aug 8.
Zotero 插件